STAAR Surgical (NASDAQ:STAA – Get Free Report) and LivaNova (NASDAQ:LIVN – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, profitability and analyst recommendations.
Earnings & Valuation
This table compares STAAR Surgical and LivaNova”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| STAAR Surgical | $239.44 million | 4.91 | -$80.45 million | $0.07 | 335.29 |
| LivaNova | $1.39 billion | 3.25 | -$242.47 million | $3.38 | 24.24 |
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for STAAR Surgical and LivaNova, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| STAAR Surgical | 3 | 8 | 2 | 0 | 1.92 |
| LivaNova | 0 | 5 | 6 | 0 | 2.55 |
STAAR Surgical currently has a consensus target price of $28.40, indicating a potential upside of 21.01%. LivaNova has a consensus target price of $84.12, indicating a potential upside of 2.69%. Given STAAR Surgical’s higher probable upside, equities analysts plainly believe STAAR Surgical is more favorable than LivaNova.
Insider & Institutional Ownership
96.7% of STAAR Surgical shares are held by institutional investors. Comparatively, 97.6% of LivaNova shares are held by institutional investors. 39.9% of STAAR Surgical shares are held by insiders. Comparatively, 0.3% of LivaNova shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Risk & Volatility
STAAR Surgical has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500.
Profitability
This table compares STAAR Surgical and LivaNova’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| STAAR Surgical | 1.13% | 9.05% | 6.99% |
| LivaNova | 12.82% | 16.35% | 7.76% |
Summary
LivaNova beats STAAR Surgical on 8 of the 14 factors compared between the two stocks.
About STAAR Surgical
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
About LivaNova
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.
